Polymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy.

IF 2.8 4区医学 Q3 ENDOCRINOLOGY & METABOLISM Discover. Oncology Pub Date : 2024-11-11 DOI:10.1007/s12672-024-01509-9

Ashish Kumar Parashar, Gaurav Kant Saraogi, Pushpendra Kumar Jain, Balakdas Kurmi, Vivek Shrivastava, Vandana Arora

{"title":"Polymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy.","authors":"Ashish Kumar Parashar, Gaurav Kant Saraogi, Pushpendra Kumar Jain, Balakdas Kurmi, Vivek Shrivastava, Vandana Arora","doi":"10.1007/s12672-024-01509-9","DOIUrl":null,"url":null,"abstract":"<p><p>Nanotheranostics, an amalgamation of therapeutic and diagnostic capabilities at the nanoscale, is revolutionizing personalized medicine. Polymer-drug conjugates (PDCs) stand at the forefront of this arena, offering a multifaceted approach to treat complex diseases such as cancer. This review explores the recent advancements in PDCs, highlighting their design principles, working mechanisms, and the therapeutic applications. We discuss the incorporation of imaging agents into PDCs that allow for real-time monitoring of drug delivery and treatment efficacy. With the aim of improving patient care, the review examines how PDCs enable targeted drug delivery, minimize side effects, and provide valuable diagnostic data, hence enhancing the precision of medical interventions. We also address the challenges facing the clinical translation of PDCs, such as scalability, regulatory hurdles, and cost-effectiveness, providing a comprehensive outlook on the future of nanotheranostics in patient management.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554983/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-024-01509-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Nanotheranostics, an amalgamation of therapeutic and diagnostic capabilities at the nanoscale, is revolutionizing personalized medicine. Polymer-drug conjugates (PDCs) stand at the forefront of this arena, offering a multifaceted approach to treat complex diseases such as cancer. This review explores the recent advancements in PDCs, highlighting their design principles, working mechanisms, and the therapeutic applications. We discuss the incorporation of imaging agents into PDCs that allow for real-time monitoring of drug delivery and treatment efficacy. With the aim of improving patient care, the review examines how PDCs enable targeted drug delivery, minimize side effects, and provide valuable diagnostic data, hence enhancing the precision of medical interventions. We also address the challenges facing the clinical translation of PDCs, such as scalability, regulatory hurdles, and cost-effectiveness, providing a comprehensive outlook on the future of nanotheranostics in patient management.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

聚合物-药物共轭物：用于诊断和治疗的纳米otheranostic制剂的革命性变革。

纳米otheranostics（纳米otheranostics）是纳米级治疗和诊断能力的综合体，正在彻底改变个性化医疗。聚合物-药物共轭物（PDCs）站在了这一领域的前沿，为治疗癌症等复杂疾病提供了多方面的方法。本综述探讨了 PDC 的最新进展，重点介绍了其设计原理、工作机制和治疗应用。我们讨论了在 PDC 中加入成像剂以实时监测药物输送和治疗效果的问题。为了改善患者护理，本综述探讨了 PDC 如何实现靶向给药、最大限度地减少副作用并提供有价值的诊断数据，从而提高医疗干预的精确性。我们还探讨了 PDC 临床转化所面临的挑战，如可扩展性、监管障碍和成本效益，全面展望了纳米otheranostics 在患者管理中的未来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊